İNTRAKAVERNOSAL SİLDENAFİLİN SIÇANLARDA DUTASTERID TEDAVİSİ SONRASI GELİŞEN EREKTIL DİSFONKSİYON ÜZERİNE YARARLI ETKİSİ
-
Published:2022-09-28
Issue:
Volume:
Page:908-918
-
ISSN:1015-3918
-
Container-title:Ankara Universitesi Eczacilik Fakultesi Dergisi
-
language:en
-
Short-container-title:Ankara Ecz. Fak. Derg.
Author:
YILMAZ ORAL Didem1, GUR Serap2
Affiliation:
1. CUKUROVA UNIVERSITY, FACULTY OF PHARMACY 2. ANKARA UNIVERSITY, FACULTY OF PHARMACY
Abstract
Objective: Benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are the most common illnesses in aged male patients. 5α-reductase inhibitors (5-ARIs) are suggested for the treatment of BPH. Furthermore, the association of 5ARIs with ED has been indicated. This study aimed to investigate the effect of intracavernosal injection of sildenafil on ED in 5ARI treated rats.Material and Method: Sprague-Dawley rats (n=30) were divided into three groups: Control; 10-week dutasteride treatment (0.5 mg/rat/day); and 6-week durasteride treatment followed by a 4-week washout period. In vivo erectile responses were assessed before and after intracavernosal injection of sildenafil (0.3mg/kg/rat). The relaxant and contractile responses of isolated corpus cavernosum were evaluated in in vitro organ bath.Result and Discussion: Prostate weight decreased after 10-week dutasteride treatment. In vivo erectile responses, endothelial and nitrergic relaxation responses were decreased in dutasteride groups. The washout period moderately normalized erectile responses. The intracavernosal injection of sildenafil increased erectile function in treatment groups. Contractile responses were augmented in 10-week dutasteride treated rats. The cessation of the treatment did not alter erectile function as well as endothelial relaxation and nitrergic relaxation. Also, intracavernosal sildenafil caused an improvement in 5ARI treatment-induced ED.
Publisher
Ankara Universitesi Eczacilik Fakultesi Dergisi
Subject
Pharmaceutical Science,Pharmacology
Reference31 articles.
1. 1. Ng, M., Baradhi, K.M., Benign Prostatic Hyperplasia, in StatPearls. 2022: Treasure Island (FL). 2. 2. Rowhrborm, C., McConnell, J.D. (2002). Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Campbell’s Urology, 37, p. 1297-1330. 3. 3. Committee, A.U.A.P.G. (2003). AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. Journal of Urology, 170(2 Pt 1), 530-547.
4. La Vignera, S., Aversa, A., Cannarella, R., Condorelli, R.A., Duca, Y., Russo, G.I., Calogero, A.E. (2021). Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opinion on Pharmacotherapy, 22(2), 179-189. [CrossRef] 4. 5. Goldenberg, L., So, A., Fleshner, N., Rendon, R., Drachenberg, D., Elhilali, M. (2009). The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Canadian Urology Association Journal, 3(3 Suppl 2), 109-114. [CrossRef] 5. 6. Kim, E.H., Brockman, J.A., Andriole, G.L. (2018). The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian Journal of Urology, 5(1), 28-32. [CrossRef]
|
|